| Revenue growth | 18% for FY26; Q4 YoY growth at 26%. |
|---|---|
| Margins | EBITDA margins expanded 420 bps to 43.4% in FY26. |
| Order book | Flow business for specialty ingredients; long-term visibility in CRDMO. |
| Demand visibility | Strong; restocking by customers follows prior destocking phase. |
| Management confidence | High; confident in 20%+ long-term growth trajectory. |
Growth
FY26 revenue grew 18% YoY to ₹2,124cr; PAT increased 31% to ₹592cr with 26% margins.
Outlook
Unit 4 capex of ₹1,200cr planned for FY27-28; targeting 20% long-term revenue growth and sustained high margins.
Risks
Challenges include inflationary pressures, geopolitical uncertainties (Middle East war), and potential capacity cannibalization by NCE projects.
Earnings Call filed with BSE, NSE: ANTHEM. Summary written with AI assistance from the document.
Anthem Biosciences Ltd: key numbers
- Share price
- ₹873.60
- Market cap
- ₹49,201 Cr
- Revenue (annual)
- ₹2,124 Cr
- Net profit (annual)
- ₹591.8 Cr
- P/E (TTM)
- 85.4×Sector 50.4×
- Promoter holding
- 71.42%-3.26% QoQ
- FII holding
- 2.57%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anthem Biosciences Ltd
All →Anthem Biosciences Other Announcement
Designated Person Viridity Tone LLP sold shares of Anthem Biosciences Ltd worth ₹82.67 Crore via market sale.
- Value
- ₹82.67 Cr
Anthem Biosciences Legal & Regulatory
Anthem Biosciences Ltd announced the settlement of an upside sharing amount of ₹127.68 Crore related to a prior divestment, following shareholder approval.
- Value
- ₹127.7 Cr
Anthem Biosciences Earnings Call Transcript: Key Takeaways
Revenue fell 25% YoY due to deferred deliveries, though management claims a record order book will drive second-half recovery. While EBITDA margins remain high at 39.6%, the quarter reflects high lumpiness in the CRDMO business.
Anthem Biosciences Investor Presentation: Key Takeaways
Anthem reported Q1FY27 revenue of ₹4,182 Mn with a 39.6% EBITDA margin. Results reflect timing shifts in deliveries, though management reports strong underlying demand and year-on-year margin improvement.
Anthem Biosciences Q1 FY27 Results: Net Profit ₹119.9 Cr, Down 11.7% YoY
Anthem Biosciences Ltd reported revenue from operations of ₹418.2 Cr (-22.6% YoY) and net profit of ₹119.9 Cr (-11.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹119.9 Cr · -11.7% YoY
Anthem Biosciences Earnings Call: Key Takeaways
Anthem delivered robust FY26 growth, overcoming destocking challenges in their core CRDMO segment.